Related Experiment Video

Updated: Jul 14, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol

Jen-Liang Su1, Ching-Yao Yang, Ming Zhao

  • 1Graduate Institute of Cancer Biology, College of Medicine, China Medical University, Taichung 404, Taiwan.

The Journal of Biological Chemistry
|May 22, 2007
PubMed

Insights

Resveratrol shows promise for treating osteoporosis by protecting bones and reducing breast cancer risk, similar to hormone replacement therapy but without the associated dangers. This natural compound offers a safer alternative for postmenopausal women.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Background:

  • Osteoporosis is a significant public health concern, with hormone replacement therapy (HRT) facing reduced use due to safety concerns like increased breast cancer and cardiovascular risks.
  • Resveratrol, a natural compound with estrogenic properties, presents a potential therapeutic agent for osteoporosis.

Purpose of the Study:

  • To evaluate the efficacy of resveratrol in preventing bone loss and reducing breast cancer risk.
  • To elucidate the molecular mechanisms underlying resveratrol's bone-protective and tumor-suppressive effects, focusing on forkhead proteins.

Main Methods:

  • In vivo and in vitro studies were conducted to assess resveratrol's effects on bone health and cancer risk.
  • Molecular analyses investigated the roles of forkhead proteins (FOXA1, FOXO3a), Src kinase, estrogen receptors, and Akt signaling pathways.

Main Results:

  • Resveratrol demonstrated bone-protective effects comparable to HRT.
  • Resveratrol reduced the risk of breast cancer in experimental models.
  • The bone-protective effect involved the induction of bone morphogenetic protein-2 via estrogen receptor activation, with FOXA1 being crucial.
  • Tumor-suppressive effects were linked to Akt inactivation and subsequent FOXO3a nuclear accumulation.

Conclusions:

  • Resveratrol offers a potentially effective and safer therapeutic strategy for postmenopausal osteoporosis management.
  • Resveratrol may mitigate osteoporosis without increasing breast cancer risk, mediated by forkhead protein pathways.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: